Pituitary Tumor Surveillance: Pathogenic Correlation

This study is currently recruiting participants.

Verified by Cedars-Sinai Medical Center, July 2009

First Received: January 11, 2008 Last Updated: July 8, 2009 History of Changes

Sponsor:	Cedars-Sinai Medical Center
Information provided by:	Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:	NCT00599092

Purpose

The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.

Condition
Pituitary Tumor

Study Type:	Observational
Study Design:	Prospective
Official Title:	Pituitary Tumor Surveillance: Pathogenetic Correlation

Resource links provided by NLM:

MedlinePlus related topics: Cancer Pituitary Tumors

U.S. FDA Resources

Further study details as provided by Cedars-Sinai Medical Center:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

whole blood

Estimated Enrollment:	1250
Study Start Date:	January 1997
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Detailed Description:

The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

tertiary referral center

Criteria

Inclusion Criteria:

patients with confirmed pituitary disease

Exclusion Criteria:

patients who do not have confirmed pituitary disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599092

Locations

United States, California
Cedars-Sinai Medical Center, Pituitary Center	Recruiting
Los Angeles, California, United States, 90048
Contact: Daniel Akers 310-423-3395 daniel.akers@cshs.org
Contact: Lori Korsakoff, RN 310-423-2411 lori.korsakoff@cshs.org
Principal Investigator: Shlomo Melmed, MD

Sponsors and Collaborators

Cedars-Sinai Medical Center

Investigators

Principal Investigator:

Shlomo Melmed, MD

Cedars-Sinai Medical Center, Pituitary Center

More Information

No publications provided

Responsible Party:	Cedars-Sinai Medical Center ( Shlomo Melmed, MD )
Study ID Numbers:	2873, 2873
Study First Received:	January 11, 2008
Last Updated:	July 8, 2009
ClinicalTrials.gov Identifier:	NCT00599092 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Cedars-Sinai Medical Center:

pituitary tumor
recurrence

Additional relevant MeSH terms:

Pituitary Neoplasms
Pituitary Diseases
Hypothalamic Diseases
Nervous System Diseases
Endocrine System Diseases
Central Nervous System Diseases
Central Nervous System Neoplasms
Brain Diseases

Supratentorial Neoplasms
Brain Neoplasms
Neoplasms
Neoplasms by Site
Hypothalamic Neoplasms
Nervous System Neoplasms
Endocrine Gland Neoplasms

ClinicalTrials.gov processed this record on February 08, 2010